ERNA

Ernexa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of metabolic diseases and other chronic conditions. The company focuses on discovering and developing small molecule drugs targeting metabolic pathways involved in conditions such as obesity, diabetes, and liver disease. Ernexa's pipeline includes multiple programs in preclinical and clinical development stages. The company employs a precision medicine approach to identify patient populations most likely to benefit from its therapeutic candidates. Further details about Ernexa's specific programs and development stage would require additional research as the company is relatively early in its public market lifecycle.